Evolocumab Production Cost Reports

The report provides a detailed analysis essential for establishing an Evolocumab production plant. It encompasses all critical aspects necessary for Evolocumab production, including the cost of Evolocumab production, Evolocumab plant cost, Evolocumab production costs, and the overall Evolocumab production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating an Evolocumab production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Evolocumab is a therapeutic monoclonal antibody mainly used in the treatment of cardiovascular disorders related to high cholesterol levels. It is widely prescribed for patients with primary hypercholesterolemia and mixed dyslipidemia, especially when standard lipid-lowering therapies do not provide sufficient control.

Evolocumab works by blocking a protein called PCSK9, which helps the liver remove more LDL cholesterol (bad cholesterol) from the blood. It is also used in individuals with familial hypercholesterolemia, which is a genetic condition that causes very high levels of low-density lipoprotein (LDL) cholesterol. It helps reduce the risk of serious heart-related events, including heart attacks and strokes, by significantly lowering LDL cholesterol levels in the blood. 
In clinical practice, it is often administered alongside statins or other lipid-lowering medicines to improve treatment outcomes. Additionally, Evolocumab plays an important role in long-term cholesterol management for patients who are intolerant to conventional therapies or require intensive LDL reduction.

The primary factor that drives the market for Evolocumab is its application as a monoclonal antibody in the treatment of severe hypercholesterolemia, which significantly boosts its demand in the medical sector. Its application as a prescription medicine given to patients with conditions like familial hypercholesterolemia or those at risk of heart disease also promotes its demand in the pharmaceutical industry. Its involvement in combination with other cholesterol-lowering medications to achieve better results also contributes to its demand in the medical and healthcare sectors.

Its demand to lower LDL cholesterol levels in patients with cardiovascular risks, especially those with familial hypercholesterolemia or a history of heart disease, largely supports its market growth. Additionally, industrial Evolocumab procurement is influenced by factors such as the high cost of biologic production, strict regulatory requirements, quality control standards, cold-chain logistics, and the availability of advanced bioproduction technologies. Further, the role of strategic partnerships with suppliers and investments in research and development plays a crucial role in maintaining a stable supply and supporting its market growth.

Raw Material for Evolocumab Production

According to the Evolocumab production plant project report, the major raw materials for Evolocumab production includes Chinese hamster ovary (CHO) cells.

Production Process of Evolocumab

The extensive Evolocumab production cost report consists of the following industrial production process:

1. Production via Recombinant DNA Technology: The production process of Evolocumab begins with the cultivation of genetically engineered Chinese hamster ovary (CHO) cells that carry the expression vector encoding the Evolocumab antibody. These cells are expanded under controlled conditions to facilitate the production of the target protein, which is secreted into the cell culture medium. After completion of the cell culture stage, the harvested cell culture fluid is collected and clarified to remove cells and debris. Then, the clarified fluid undergoes a series of purification steps, including chromatography and filtration, to remove process-related impurities, host cell proteins, and other unwanted components. The complete process results in the formation of purified Evolocumab as the final drug substance.

Evolocumab is a fully human monoclonal antibody belonging to the immunoglobulin G2 (IgG2) subclass. The compound appears as a clear to opalescent, colourless to pale yellow solution that is sterile and preservative-free, and is practically free from visible particles. It functions as a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor used for the treatment of hyperlipidemia and hypercholesterolemia. The molecular weight of Evolocumab is approximately 144 kDa, and the molecular structure consists of two heavy chains and two light chains of the lambda subclass. Evolocumab must be stored refrigerated at 2 degree Celsius to 8 degree Celsius in the original carton to protect it from light, and it should not be frozen or shaken. The compound exhibits temperature sensitivity and loses its effectiveness after prolonged exposure to elevated temperatures. It is administered as a subcutaneous injection and is available in various formulations, including prefilled syringes, prefilled autoinjectors, and on-body infusor systems. The compound should not be used if the solution is discoloured, cloudy, or contains particulate matter, and it is intended for single-use only, as it contains no preservatives.